This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.90% per year. These returns cover a period from January 1, 1988 through December 1, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
pot-stocks: Archive
Curaleaf Announces Delaware Domestication Plan: How to Play the Stock?
by Sundeep Ganoria
CURLF's Delaware domestication plan could streamline governance and enhance capital market flexibility as U.S. pressure persists and international growth builds.
CGCNegative Net Change TLRYNegative Net Change ACBNegative Net Change CURLFNegative Net Change
marijuana medical pot-stocks
Should You Buy ACB Stock After Marijuana Reclassification Order?
by Sundeep Ganoria
Aurora Cannabis faces uneven gains from marijuana reclassification as medical cannabis drives growth, while weak consumer sales affect optimism.
CGCNegative Net Change TLRYNegative Net Change ACBNegative Net Change
marijuana medical pot-stocks
Should You Buy GTBIF Stock After Marijuana Reclassification Order?
by Sundeep Ganoria
Shares of Green Thumb GTBIF jump nearly 35% on a marijuana rescheduling order, but pricing pressure and weak comps cloud the stock's near-term outlook.
CGCNegative Net Change GTBIFNegative Net Change CRLBFNegative Net Change
marijuana medical pot-stocks
Why Jazz Pharmaceuticals May Be a Stealth Cannabis Winner
by Sundeep Ganoria
JAZZ leverages Epidiolex's rising sales and its broad drug portfolio to strengthen its position in the evolving medical cannabis market.
JAZZNegative Net Change TLRYNegative Net Change VRNONegative Net Change
biotechs marijuana medical pot-stocks
3 Cannabis Stocks to Watch After Trump's Marijuana Rescheduling Signal
by Sundeep Ganoria
Trump's marijuana rescheduling remarks reignite cannabis optimism, putting Village Farms, Canopy Growth and High Tide in focus.
CGCNegative Net Change VFFNegative Net Change HITIPositive Net Change
marijuana medical pot-stocks
Can Cannabis Stocks Reverse Their Prolonged Downtrend?
by Sundeep Ganoria
Cannabis stocks like TLRY and GTBIF remain deep in years-long slump, but U.S. federal reform or global expansion could ignite a long-awaited rebound.
CRBPPositive Net Change CGCNegative Net Change TLRYNegative Net Change HRMYNegative Net Change GTBIFNegative Net Change
biotechs marijuana medical pot-stocks
Should You Buy, Hold or Sell TLRY Stock Post Q4 Earnings Release?
by Sundeep Ganoria
Tilray posts record non-cannabis revenues in fiscal 2025, but Q4 sales slip as cannabis weakness pressures overall results.
CGCNegative Net Change TLRYNegative Net Change ACBNegative Net Change CURLFNegative Net Change
earnings marijuana medical pot-stocks
Cannabis Operator CRLBF Plans California Exit: How to Play the Stock?
by Sundeep Ganoria
Cresco plans to exit California, citing tough market dynamics, as it sharpens focus on high-margin growth markets.
TLRYNegative Net Change GTBIFNegative Net Change CRLBFNegative Net Change CURLFNegative Net Change
marijuana medical pot-stocks
Cannabis Stock Cresco Labs Plunges 24% YTD: Time to Sell or Hold?
by Sundeep Ganoria
CRLBF is down 24% YTD as U.S.-only exposure, falling margins and tighter regulations weigh on its cannabis business.
CGCNegative Net Change TLRYNegative Net Change ACBNegative Net Change CRLBFNegative Net Change
marijuana medical pot-stocks
Cannabis Operator Curaleaf Plunges 46% YTD: Time to Sell or Hold?
by Sundeep Ganoria
CURLF dives 46% YTD as domestic headwinds outweigh global growth; is it time to cash out or wait for a rebound?
CGCNegative Net Change TLRYNegative Net Change ACBNegative Net Change CURLFNegative Net Change
marijuana medical pot-stocks
Could the New Federal Bill Derail the U.S. Hemp Industry?
by Sundeep Ganoria
A proposed federal bill could upend the U.S. hemp market, threatening CBD and Delta-8 products now sold nationwide.
CGCNegative Net Change TLRYNegative Net Change CURLFNegative Net Change
marijuana medical pot-stocks
Cannabis Stock CGC Rallies 39% in Three Months: Time to Buy or Sell?
by Sundeep Ganoria
Canopy Growth surges 39% in three months as restructuring, margin gains and debt cuts renew investor interest.
CGCNegative Net Change TLRYNegative Net Change ACBNegative Net Change VFFNegative Net Change
marijuana medical pot-stocks
Cannabis Operator VFF Sells Fresh Produce Unit: How to Play the Stock?
by Sundeep Ganoria
After dropping its produce business, Village Farms sharpens its cannabis focus - boosting exports, margins and market share.
CGCNegative Net Change TLRYNegative Net Change ACBNegative Net Change VFFNegative Net Change
marijuana medical pot-stocks
Aurora Cannabis Stock Rises 30% YTD: Time to Buy or Sell?
by Sundeep Ganoria
ACB's 30% YTD rally reflects Q3 strength, but flat EPS estimates and consumer weakness keep analysts cautious about long-term upside.
CGCNegative Net Change TLRYNegative Net Change ACBNegative Net Change
marijuana medical pot-stocks
Cannabis Stock Tilray Brands Loses 19% in a Month: Time to Sell or Hold?
by Sundeep Ganoria
TLRY's pivot into beverages shows promise, but with falling cannabis sales and delisting risks, we recommend staying on the sidelines for now.
PMPositive Net Change JAZZNegative Net Change CRBPPositive Net Change TLRYNegative Net Change
marijuana medical pot-stocks
3 Unconventional Cannabis Stocks to Watch in 2025
by Sundeep Ganoria
Think cannabis investing is all hype? These three unconventional stocks could change your mind - and your portfolio - in 2025.
PMPositive Net Change JAZZNegative Net Change CRBPPositive Net Change
biotechs marijuana medical pharmaceuticals pot-stocks
Cardiol Therapeutics Stock: Is Cannabis Potential Priced In?
by Sundeep Ganoria
Cardiol Therapeutics shows promise with its CBD-based heart therapy, but a lack of approved drugs and a narrow pipeline raise red flags for cautious investors.
JAZZNegative Net Change KNSAPositive Net Change CRDLPositive Net Change
biotechs marijuana medical pot-stocks
Is Jazz Pharmaceuticals a Top Cannabis Investment for 2025?
by Sundeep Ganoria
Not your typical cannabis play. Discover why Jazz Pharma's FDA-approved CBD drug could make it a top cannabis stock to watch in 2025.
JAZZNegative Net Change TLRYNegative Net Change
biotechs marijuana medical pot-stocks
Is Tilray Brands (TLRY) A Buy Ahead of Fiscal Q3 Earnings Announcement?
by Bryan Hayes
Industry headwinds still present a major challenge.
TLRYNegative Net Change
cannabis earnings investing marijuana meme-stocks pot-stocks
3 Hot Cannabis Stocks That Should be on Your Watchlist
by Tirthankar Chakraborty
Cannabis stocks are set to be the rage on Wall Street in hopes of legalization in the US. Thus, keep an eye on stocks like Tilray (TLRY), Innovative Industrial Properties (IIPR) & GrowGeneration (GRWG).
IIPRNegative Net Change GRWGNegative Net Change TLRYNegative Net Change
marijuana pot-stocks
Innovative Industrial (IIPR) Expands Maryland Base With Buyout
by Zacks Equity Research
Innovative Industrial's (IIPR) Maryland property buyout and tie-up with a subsidiary of Harvest to help the REIT bank on solid opportunities in the company's markets and boost its top line.
PSAPositive Net Change EXRPositive Net Change OUTPositive Net Change IIPRNegative Net Change
finance marijuana pot-stocks reit
Innovative Industrial (IIPR) Cheers Investors With Dividend Hike
by Zacks Equity Research
Innovative Industrial's (IIPR) nearly 6.5% sequential dividend hike reflects its tenth dividend increase since this cannabis-focused real estate company completed its initial public offering in December 2016.
EXRPositive Net Change GNLPositive Net Change IIPRNegative Net Change PINEPositive Net Change
finance marijuana pot-stocks
Innovative Industrial (IIPR) Buys Texas Asset, Boosts Portfolio
by Zacks Equity Research
Expansion of portfolio with the Texas property buyout and tie-up with Parallel can help Innovative Industrial Properties (IIPR) benefit from favorable trends while driving its top line.
EXRPositive Net Change GNLPositive Net Change IIPRNegative Net Change PINEPositive Net Change
finance marijuana pot-stocks reit
Key Factors to Impact Innovative Industrial (IIPR) Q4 Earnings
by Zacks Equity Research
With several states in the United States giving cannabis the green light, Innovative Industrial's (IIPR) investment in such properties is likely to have aided its Q4 performance.
AMTPositive Net Change PSAPositive Net Change CUBEPositive Net Change IIPRNegative Net Change
earnings finance marijuana pot-stocks reit
Scotts Miracle-Gro (SMG) Q4 Earnings Lag Estimates, Sales Top
by Zacks Equity Research
In Q4, Scotts Miracle-Gro (SMG) delivers growth in the U.S. Consumer and Hawthorne segments across all product categories, geographies and retail channels.
GOLDPositive Net Change SMGNegative Net Change AEMNegative Net Change BTGNegative Net Change
basic-materials marijuana pot-stocks